Publications

Detailed Information

BRCA1 및BRCA2 유전자 돌연변이에 기인한 한국인 유방암 및 난소암 위험도: 예비 연구 결과 보고 : The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report

DC Field Value Language
dc.contributor.author한상아-
dc.contributor.author박수경-
dc.contributor.author안세현-
dc.contributor.author손병호-
dc.contributor.author이민혁-
dc.contributor.author최두호-
dc.contributor.author노동영-
dc.contributor.author한원식-
dc.contributor.author이은숙-
dc.contributor.author한서경-
dc.contributor.author김이수-
dc.contributor.author정용식-
dc.contributor.author김구상-
dc.contributor.author서영진-
dc.contributor.author문병인-
dc.contributor.author남석진-
dc.contributor.author노우철-
dc.contributor.author이정언-
dc.contributor.author김성원-
dc.date.accessioned2012-06-08T08:03:03Z-
dc.date.available2012-06-08T08:03:03Z-
dc.date.issued2009-06-
dc.identifier.citationJOURNAL OF BREAST CANCER; Vol.12 2; 92-99ko_KR
dc.identifier.issn1738-6756-
dc.identifier.urihttps://hdl.handle.net/10371/76930-
dc.description본 논문은 2007 Global Breast Cancer Conference (GBCC)에서 포스터 발표되었음.ko_KR
dc.description.abstractPurpose: To estimate the cumulative risk till each age (penetrance) of breast and ovarian cancers among female family members with BRCA1 and BRCA2 mutation. Methods: Among the 61 BRCA1 mutation carriers in the 42 families and 47 BRCA2 mutation carriers in 31 families identified at 5 academic breast clinics, the probands were excluded to estimate the cumulative risk till each age of breast cancer in the Korean BRCA1 and BRCA2 carriers. Using Kaplan-Meier analyses, cumulative cancer risk estimates were determined. Results: By the age 70, the female breast cancer risk for the BRCA1 and BRCA2 mutation carriers was 72.1% (95% confidence interval [CI]=59.5% to 84.8%) and 66.3% (95% CI=41.2% to 91.5%), respectively, and the ovarian cancer risk was 24.6% (95% CI=0% to 50.3%) and 11.1% (95% CI=0% to 31.6%), respectively. The contralateral breast cancer risk at 5 years after primary breast cancer was estimated as 16.2% (95% CI=9.3% to 23.1%) for the 52 breast cancer patients with the BRCA1 mutation and 17.3% (95% CI=9.7% to 24.0%) for the 35 breast cancer patients with the BRCA2 mutation. Conclusion: The penetrance of BRCA mutations in Korea is largely consistent with the previous studies on Western populations. However, the small number of the cases, the high proportions of probands in the study subjects, the short term follow-up, and large confidence intervals are the limitations of the current study. The Korean Hereditary Breast Cancer Study (KOHBRA Study) may definitely answer this question.ko_KR
dc.language.isokoko_KR
dc.publisherKOREAN BREAST CANCER SOCko_KR
dc.subjectBreast neoplasmsko_KR
dc.subjectOvarian neoplasmsko_KR
dc.subjectRiskko_KR
dc.subjectPenetrance of BRCA mutationko_KR
dc.subject유방암ko_KR
dc.subject난소암ko_KR
dc.subjectBRCA 돌연변이의 침투율ko_KR
dc.subject위험도ko_KR
dc.titleBRCA1 및BRCA2 유전자 돌연변이에 기인한 한국인 유방암 및 난소암 위험도: 예비 연구 결과 보고ko_KR
dc.title.alternativeThe Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Reportko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthorHan, Sang Ah-
dc.contributor.AlternativeAuthorPark, Sue K.-
dc.contributor.AlternativeAuthorAhn, Sei-Hyun-
dc.contributor.AlternativeAuthorSon, Byung Ho-
dc.contributor.AlternativeAuthorLee, Min Hyuk-
dc.contributor.AlternativeAuthorChoi, Doo Ho-
dc.contributor.AlternativeAuthorNoh, Dong-Young-
dc.contributor.AlternativeAuthorHan, Wonshik-
dc.contributor.AlternativeAuthorLee, Eun Sook-
dc.contributor.AlternativeAuthorHan, Seo Kyung-
dc.contributor.AlternativeAuthorKim, Lee Su-
dc.contributor.AlternativeAuthorJung, Yongsik-
dc.contributor.AlternativeAuthorKim, Ku Sang-
dc.contributor.AlternativeAuthorSuh, Young Jin-
dc.contributor.AlternativeAuthorMoon, Byung-In-
dc.contributor.AlternativeAuthorNam, Seok-Jin-
dc.contributor.AlternativeAuthorNoh, Woo-Chul-
dc.contributor.AlternativeAuthorLee, Jeong Eon-
dc.contributor.AlternativeAuthorKim, Sung-Won-
dc.identifier.doi10.4048/jbc.2009.12.2.92-
dc.citation.journaltitleJOURNAL OF BREAST CANCER-
dc.description.citedreferenceKim KS, 2008, J BREAST CANCER, V11, P95-
dc.description.citedreferenceKim EK, 2007, J BREAST CANCER, V10, P241-
dc.description.citedreferenceVogl FD, 2007, FAM CANCER, V6, P63, DOI 10.1007/s10689-006-9106-8-
dc.description.citedreferenceAhn SH, 2007, CANCER LETT, V245, P90, DOI 10.1016/j.canlet.2005.12.031-
dc.description.citedreferenceSchlich-Bakker KJ, 2006, PATIENT EDUC COUNS, V62, P13, DOI 10.1016/j.pec.2005.08.012-
dc.description.citedreferenceMetcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033-
dc.description.citedreferenceChoi DH, 2004, J CLIN ONCOL, V22, P1638, DOI 10.1200/JCO.2004.04.179-
dc.description.citedreferenceKing MC, 2003, SCIENCE, V302, P643-
dc.description.citedreferenceAntoniou A, 2003, AM J HUM GENET, V72, P1117-
dc.description.citedreferenceKauff ND, 2003, CANCER, V97, P1601, DOI 10.1002/cncr.11225-
dc.description.citedreferenceLiede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154-
dc.description.citedreferenceBrose MS, 2002, J NATL CANCER I, V94, P1365-
dc.description.citedreferenceIKEDA N, 2002, J BREAST CANCER, V5, P194-
dc.description.citedreferenceEng C, 2001, J MED GENET, V38, P824-
dc.description.citedreferenceRisch HA, 2001, AM J HUM GENET, V68, P700-
dc.description.citedreferenceROBSON ME, 2001, CURR PROB SURG, V38, P387-
dc.description.citedreferencePonder BAJ, 2000, BRIT J CANCER, V83, P1301-
dc.description.citedreferenceMatloff ET, 2000, J CLIN ONCOL, V18, P2484-
dc.description.citedreferenceWagner TMU, 2000, BRIT J CANCER, V82, P1249-
dc.description.citedreferenceJulian-Reynier C, 2000, EUR J HUM GENET, V8, P204-
dc.description.citedreferenceSchrag D, 2000, JAMA-J AM MED ASSOC, V283, P617-
dc.description.citedreferenceAntoniou AC, 2000, GENET EPIDEMIOL, V18, P173-
dc.description.citedreferenceArnold N, 1999, HUM MUTAT, V14, P333-
dc.description.citedreferenceNewman B, 1998, JAMA-J AM MED ASSOC, V279, P915-
dc.description.citedreferenceFord D, 1998, AM J HUM GENET, V62, P676-
dc.description.citedreferenceClaus EB, 1996, CANCER, V77, P2318-
dc.description.citedreferenceNieto FJ, 1996, AM J EPIDEMIOL, V143, P1059-
dc.description.citedreferenceFORD D, 1995, AM J HUM GENET, V57, P1457-
dc.description.citedreferenceEASTON DF, 1995, AM J HUM GENET, V56, P265-
dc.description.citedreferenceFORD D, 1994, LANCET, V343, P692-
dc.description.citedreferenceKAPLAN EL, 1958, J AM STAT ASSOC, V53, P457-
dc.description.tc6-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share